The BCR-ABL1 targeting TK inhibitor (TKI) imatinib was found to downregulate IL-6 and IL-8 release in primary CML cells in vitro [93]. The gene discussed is CXCL8; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.